CellCarta

What began as the merging of two pioneering entities, Caprion Biosciences and HistoGeneX, in 2019 has flourished into CellCarta, a global leader in precision medicine and biomarker development. Headquartered in Montreal, Canada, CellCarta stands at the forefront of contract research organizations (CROs), catering to the diverse needs of the biopharmaceutical industry. This evolution reflects an unwavering commitment to enhancing drug development through innovative laboratory services and a robust understanding of biomarker complexities.

Emphasizing the journey towards patient-centric therapies, CellCarta provides an extensive range of technologies, including innovative solutions in histopathology, immunology, genomics, and proteomics. With as many as ten operational facilities across the globe—including locations in the USA, Belgium, Australia, and China—CellCarta pairs local expertise with global reach, effectively navigating regulatory environments to ensure compliance and expedite clinical trials. Their sophisticated data capabilities, including advanced flow and mass cytometry, enable comprehensive analytics to support all phases of drug development, from discovery through to clinical implementation.